The Lanzhou Heavy Ion Center has completed a clinical analysis of 61 rectal cancer patients treated with heavy (carbon) ion therapy, achieving a median survival time of 54 months. For patients with stage III/IV or recurrent/refractory disease, this technology offers significantly extended survival due to its high precision, low side effects, and sphincter-sparing advantages, providing a new treatment option for those ineligible for surgery or resistant to radiotherapy and chemotherapy.

Cardiac tumors, whether primary or secondary, have long been a challenge in tumor treatment. Surgical risks are high, chemotherapy and conventional radiotherapy offer limited efficacy, and targeted drugs with clear targets are scarce, often leaving patients in a desperate situation. At the Wuwei Heavy Ion Center, we are transforming this reality by leveraging the precision, efficiency, low toxicity, and ability of heavy ions to specifically shatter tumor DNA double strands.

Introduction to the definition of superficial refractory tumors and the three core advantages of heavy (carbon) ion therapy: precise targeting via the Bragg peak, ultra-high biological effectiveness, and flexible dose modulation. The Gansu Wuwei Heavy Ion Center, utilizing domestically produced equipment, has successfully treated over 2,800 difficult cases—including sarcomas and recurrent breast cancer on the chest wall—that had failed conventional therapies, offering new hope to patients who had lost all hope.

The Wuyi Heavy Ion Center's HFOV technology achieves respiratory motion control within 1mm, enhancing the accuracy of heavy ion radiotherapy. By using high-frequency oscillatory ventilation, it ensures the stability of the tumor target area, improving treatment safety and efficacy.

A summary analysis of 77 cases of chordoma treated with heavy ion (carbon ion) therapy at the Wuwei Heavy Ion Medical Center, demonstrating its high efficacy and low toxicity, suitable for patients with complex and large chordomas, especially those who are difficult to resect surgically or have recurrent after surgery.

Since the first heavy ion device in China was established in Wuwei, Gansu in 2012, we have developed an inseparable connection with particle therapy for cancer. From that time on, we embarked on the journey of constructing China's first heavy ion device.

A real-world data study of 170 cases of liver cancer treated with heavy ion therapy in Wuwei reveals survival breakthroughs, with a median survival period of 37 months and a 5-year survival rate of 41.01%, demonstrating the outstanding value of China's advanced technology in the treatment of liver cancer.

Brain tumors are the focus and difficulty in the field of radiation therapy, mainly including two types: primary brain gliomas and secondary brain metastases. The Wuwei Heavy Ion Center, relying on China's first heavy (carbon) ion therapy system, has accumulated rich clinical experience in the treatment of brain tumors. Since the first patient received heavy (carbon) ion therapy in November 2018, as of March 2026, the center has treated a total of 198 patients with brain tumors, including 76 patients with brain gliomas and 122 patients with brain metastases, totaling 198 cases of brain tumors.